1. Home
  2. DLHC vs BMEA Comparison

DLHC vs BMEA Comparison

Compare DLHC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DLH Holdings Corp.

DLHC

DLH Holdings Corp.

N/A

Current Price

$2.88

Market Cap

50.9M

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$0.59

Market Cap

42.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLHC
BMEA
Founded
1969
2017
Country
United States
United States
Employees
2300
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.9M
42.4M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
DLHC
BMEA
Price
$2.88
$0.59
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $6.17
AVG Volume (30 Days)
9.2K
★ 1.0M
Earning Date
12-09-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.19
EPS
N/A
★ N/A
Revenue
★ $41,923,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 2.57
N/A
52 Week Low
$2.86
$0.45
52 Week High
$6.88
$2.24

Technical Indicators

Market Signals
Indicator
DLHC
BMEA
Relative Strength Index (RSI) 23.12 39.17
Support Level N/A $0.55
Resistance Level $4.05 $0.69
Average True Range (ATR) 0.20 0.07
MACD -0.08 0.02
Stochastic Oscillator 0.90 55.37

Price Performance

Historical Comparison
DLHC
BMEA

About DLHC DLH Holdings Corp.

DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: